Yung Zip Chemical Ind. Co., Ltd. AI Stock Analysis
Yung Zip Chemical Ind. Co., Ltd. (4102) AI Stock Analysis
Yung Zip Chemical Ind. Co., Ltd.
(TPEx:4102)
The overall score is weighed down primarily by sharply weaker profitability and cash generation. A relatively strong balance sheet and high dividend yield provide support, while below-average moving averages and negative MACD confirm a weak technical trend despite oversold momentum readings.
Yung Zip Chemical Ind. Co., Ltd. (4102) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 745.78M
- Dividend Yield
- 6.57%
- Average Volume (3M)
- 24.27K
- Price to Earnings (P/E)
- -905.6
- Beta (1Y)
- 0.31
- Revenue Growth
- 7.67%
- EPS Growth
- 86.29%
- Country
- TW
- Employees
- 181
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - General
Yung Zip Chemical Ind. Co., Ltd. Business Overview & Revenue Model
Company Description
Yung Zip Chemical Ind. Co., Ltd. is a global provider specializing in the manufacture of essential pharmaceutical components. The company supplies active pharmaceutical ingredients (APIs), their intermediate precursors, and various specialty chemical...
Yung Zip Chemical Ind. Co., Ltd. Financial Statement Overview
Summary
Financial performance is weak overall: the income statement score is 24.0 and cash flow score is 20.0, reflecting a sharp decline in revenue and margins, a net loss, and negative free cash flow. The balance sheet is comparatively strong with a 72.0 score, moderate debt, and a 0.27 debt-to-equity ratio. The weighted component score is constrained to the permitted minimum range and is 37.2.
Income Statement
24NegativeBalance Sheet
72PositiveCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 494.04M | 474.22M | 583.70M | 559.15M | 567.33M | 477.60M |
| Gross Profit | 103.03M | 94.57M | 178.40M | 173.89M | 164.97M | 104.51M |
| EBITDA | 28.54M | 17.00M | 113.72M | 106.58M | 117.16M | 49.84M |
| Net Income | 1.13M | -14.36M | 64.61M | 62.51M | 69.99M | 6.00M |
Balance Sheet | ||||||
| Total Assets | 951.87M | 924.11M | 964.63M | 990.27M | 1.03B | 930.25M |
| Cash, Cash Equivalents and Short-Term Investments | 90.37M | 95.04M | 133.53M | 124.11M | 144.18M | 78.20M |
| Total Debt | 163.78M | 157.41M | 102.89M | 152.29M | 214.29M | 252.59M |
| Total Liabilities | 271.94M | 256.81M | 222.61M | 282.49M | 345.94M | 353.87M |
| Stockholders Equity | 599.16M | 588.26M | 664.37M | 635.58M | 613.57M | 514.11M |
Cash Flow | ||||||
| Free Cash Flow | -2.25M | -36.57M | 80.17M | 69.31M | 66.40M | 46.09M |
| Operating Cash Flow | 20.18M | 2.10M | 118.67M | 96.76M | 92.55M | 73.27M |
| Investing Cash Flow | -23.83M | -41.61M | -25.05M | -17.77M | 16.80M | -35.34M |
| Financing Cash Flow | -11.67M | -439.00K | -86.44M | -97.36M | -44.34M | -13.13M |
Yung Zip Chemical Ind. Co., Ltd. Peers Comparison
Overall Rating
TW:410242Neutral
TW:417140Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4102 | Yung Zip Chemical Ind. Co., Ltd. | 17.50 | -4.95 | -22.05% | |
| TW:4117 | General Biologicals Corp. | 7.41 | -4.79 | -39.26% | |
| TW:4171 | GeneReach Biotechnology Corp. | 15.50 | -4.55 | -22.69% | |
| TW:4724 | Meribank Biotech Co Ltd | 9.12 | -7.83 | -46.19% | |
| TW:4732 | Naturewise Biotech & Medicals Corporation | 15.20 | -4.90 | -24.38% | |
| TW:6493 | TTBIO CORP. | 28.80 | -0.30 | -1.03% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
